Lilly opens early access to a weight-loss drug

By Vikram Singh · 2026-08-04

What Lilly confirmed

Eli Lilly confirmed on 3 August 2026 it will open a formal expanded access pathway for retatrutide, its investigational triple-agonist obesity drug. The decision came six weeks after the company granted a single compassionate-use request for a 79-year-old patient, a move that became public and drew sharp complaints from physicians who wanted the same option for their own patients.

The announcement does not hand anyone a prescription; it opens a queue. Patients must still meet FDA eligibility thresholds, treating physicians must submit individual requests, and Lilly retains the right to decline on safety or supply grounds.

How the FDA pathway actually works

The mechanism beneath this decision is 21 CFR 312 subpart I, the regulatory spine of the FDA's expanded access framework. The FDA defines expanded access, sometimes called compassionate use, as a pathway for patients with serious or immediately life-threatening conditions to gain access to investigational medical products outside clinical trials when no satisfactory approved therapy exists.^[1] The manufacturer, the treating physician, an institutional review board and the FDA all participate before any approval is granted.

In April 2026, the FDA issued final guidance on how manufacturers and clinicians should navigate these requests.^[2] That guidance clarified the conditions under which a single-patient request can be processed quickly, typically within days for emergency cases. FDA pharmacist Mary Kremzner said expanded access allows patients to use investigational drugs outside of clinical trials.^[3]

The pathway is designed to sit alongside clinical development, not replace it. The FDA requires that expanded access not interfere materially with ongoing trials, which is one reason pharmaceutical companies sometimes resist broadening access before an approval filing is secured.

Why retatrutide is in such demand

Retatrutide is not just another GLP-1 drug. It simultaneously activates three hormone receptors: GIP, GLP-1 and glucagon, and no currently approved obesity treatment operates on all three pathways at once.

Semaglutide, the active ingredient in Ozempic and Wegovy, produced around 15% average body-weight reduction in its pivotal trials. Tirzepatide, Lilly's own approved dual agonist sold as Zepbound, reached roughly 20% in its best-performing cohort. Retatrutide at the 12 mg once-weekly dose produced an average 28.3% body-weight reduction, equivalent to 70.3 pounds, over 80 weeks in TRIUMPH-1.^[4] For patients who have already cycled through approved options, that gap represents a different order of magnitude.

The glucagon receptor component adds a metabolic dimension the GLP-1 class alone does not fully cover. Glucagon activation increases energy expenditure, meaning the drug attacks excess weight from two directions: appetite suppression through GIP and GLP-1, and calorie burn through glucagon.

What the Phase 3 data show

TRIUMPH-1 was the headline result, announced on 21 May 2026, but Lilly's regulatory filing strategy rests on more than one dataset. On 23 July 2026, Lilly released topline results from TRIUMPH-2 and TRIUMPH-3, two additional Phase 3 studies targeting populations with complicating conditions.^[5]

TRIUMPH-2 enrolled adults with obesity and type 2 diabetes, a cohort where weight-loss drugs historically underperform. That group lost up to 20.8% of body weight, or 49.6 pounds, at 80 weeks, while adults with severe obesity and cardiovascular disease in TRIUMPH-3 lost up to 22.6%, or 55.8 pounds, over the same period.^[5] Both trials also showed meaningful improvements in HbA1c, the standard marker for blood-sugar control.

Kenneth Custer, Lilly's Executive Vice President and President of Cardiometabolic Health, said the company now has the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnoea, and that Lilly looks forward to working with regulators as they evaluate this first-of-its-kind medicine.^[5] Lilly plans to submit a Biologics License Application to the FDA in the first quarter of 2027.^[5]

The fairness question expanded access cannot fully answer

When it became public that Lilly had granted a one-off compassionate-use request for a 79-year-old patient, physicians treating patients with equally serious obesity-related conditions began asking why their patients were excluded. The implicit question was about who gets access to a drug before approval, and whether the answer is being shaped by connection rather than clinical need.

Expanded access does not eliminate that concern; it redistributes it. The pathway is still gatekept by the FDA's eligibility criteria, by Lilly's own willingness to approve individual requests, and by the practical reality that navigating a compassionate-use application requires a physician with the time and knowledge to do so. Patients without specialist care, or in health systems without dedicated pharmaceutical liaison staff, are less likely to reach the front of whatever queue now exists.

Custer said that across five positive Phase 3 studies, retatrutide has shown powerful efficacy, and that Lilly believes it could be an important future tool in the management of cardiometabolic health.^[5] Lilly's approval filing is scheduled for the first quarter of 2027.

Vikram Singh

Vikram Singh writes about banking. He follows where money actually moves, from the strategy set in head office to what changes on a customer's phone.